6500 Trans-Canada Highway
Pointe-Claire, QC H9R 0A5
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 3
|Dr. Steve N. Slilaty Ph.D.||Chairman, CEO & Pres||177k||N/A||1952|
|Mr. Camille Sebaaly||CFO & Sec.||20k||N/A||1959|
|Dr. Abderrazzak Merzouki||COO & Director||24.93k||N/A||1964|
|Mr. Robert G. Ferreira||Pres of Sunshine Bio Investments Inc||N/A||N/A||1962|
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also provides generic prescription drugs for the treatment of breast cancer, prostate cancer, and benign prostatic hyperplasia; and Essential 9, a dietary supplement tablet. Sunshine Biopharma, Inc. has a license agreement with the University of Georgia to advance the development of two anti-coronavirus compounds in parallel with its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. was founded in 2006 and is headquartered in Pointe-Claire, Canada.
Sunshine Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.